NASDAQ:CDNA
CareDx Stock News
$7.76
-0.440 (-5.37%)
At Close: Apr 30, 2024
CareDx Reports Fourth Quarter and Full Year 2021 Results
09:01pm, Thursday, 24'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the fourth quarter and full year ended December 31, 2021.
CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript
08:46pm, Thursday, 24'th Feb 2022
CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
01:01pm, Thursday, 24'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Appoints COO David Hering As Interim CEO
Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th
CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World''s First Successful Living Xenotransplantation
12:00pm, Tuesday, 22'nd Feb 2022 Benzinga
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world''s first successful heart xenotransplantation. A genetically modified pig heart was successfully transplanted into a patient at the University of Maryland Medical Center on January 7, 2022. Surgeons from the University of Maryland School of Medicine (UMSOM) are using adapted versions of two complementary, non-invasive CareDx surveillance solutions, experimentally, to provide a comprehensive, multimodal assessment of organ graft health. Gene expression profiling is being used to assess immune quiescence and donor-derived cell-free DNA (dd-cfDNA) to detect graft injury. "As an innovator in organ transplant surveillance, CareDx is proud to be working with UMSOM on this landmark case which represents a groundbreaking moment in the history of transplantation," said Reg Seeto, CEO and President of CareDx. "It''s incredibly rewarding to apply our years of experience and dedication to the transplant community by offering the world''s first biomarker surveillance solution for xenotransplantation.
CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring Worlds First Successful Living Xenotransplantation
12:00pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Thursday, 17'th Feb 2022 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
04:01pm, Thursday, 17'th Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically dif
On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant
12:00pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need More than 100,000 Americans Are on the National
Now Is The Time To Build A Position In CareDx Inc (NASDAQ:CDNA)
03:00pm, Saturday, 12'th Feb 2022 Marketing Sentinel
CareDx Inc (NASDAQ:CDNA)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 0.67. At the close of trading, the stocks price was $43.20, to imply a decrease of -2.33% or -$1.03 in intraday trading. The CDNA shares 52-week high remains $96.88, putting it -124.26% down since that peak Now Is The Time To Build A Position In CareDx Inc (NASDAQ:CDNA) Read More »
CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients
12:00pm, Monday, 07'th Feb 2022 GlobeNewswire Inc.
CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure CareDx Supported Education Ai
CareDx To Participate In Upcoming Conferences
12:00pm, Thursday, 03'rd Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically di
CareDx To Participate In Upcoming Conferences
07:00am, Thursday, 03'rd Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically diff
CareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities
12:00pm, Thursday, 20'th Jan 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically di